End stage renal disease‐induced hypercalcemia may promote aortic valve calcification via Annexin VI enrichment of valve interstitial cell derived‐matrix vesicles
Open Access
- 24 May 2017
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 232 (11) , 2985-2995
Abstract
Patients with end‐stage renal disease (ESRD) have elevated circulating calcium (Ca) and phosphate (Pi), and exhibit accelerated progression of calcific aortic valve disease (CAVD). We hypothesized that matrix vesicles (MVs) initiate the calcification process in CAVD. Ca induced rat valve interstitial cells (VICs) calcification at 4.5 mM (16.4‐fold; p < 0.05) whereas Pi treatment alone had no effect. Ca (2.7 mM) and Pi (2.5 mM) synergistically induced calcium deposition (10.8‐fold; p < 0.001) in VICs. Ca treatment increased the mRNA of the osteogenic markers Msx2, Runx2, and Alpl (p < 0.01). MVs were harvested by ultracentrifugation from VICs cultured with control or calcification media (containing 2.7 mM Ca and 2.5 mM Pi) for 16 hr. Proteomics analysis revealed the marked enrichment of exosomal proteins, including CD9, CD63, LAMP‐1, and LAMP‐2 and a concomitant up‐regulation of the Annexin family of calcium‐binding proteins. Of particular note Annexin VI was shown to be enriched in calcifying VIC‐derived MVs (51.9‐fold; p < 0.05). Through bioinformatic analysis using Ingenuity Pathway Analysis (IPA), the up‐regulation of canonical signaling pathways relevant to cardiovascular function were identified in calcifying VIC‐derived MVs, including aldosterone, Rho kinase, and metal binding. Further studies using human calcified valve tissue revealed the co‐localization of Annexin VI with areas of MVs in the extracellular matrix by transmission electron microscopy (TEM). Together these findings highlight a critical role for VIC‐derived MVs in CAVD. Furthermore, we identify calcium as a key driver of aortic valve calcification, which may directly underpin the increased susceptibility of ESRD patients to accelerated development of CAVD.Keywords
Funding Information
- Wellcome Trust (WT103782AIA)
- British Heart Foundation (CH/09/002, FS/12/84)
- Biotechnology and Biological Sciences Research Council (BB/F023928/1, BB/J004316/1, BB/K011618/1)
This publication has 45 references indexed in Scilit:
- Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery diseaseInternational Journal of Cardiology, 2013
- A protective role for FGF-23 in local defence against disrupted arterial wall integrity?Molecular and Cellular Endocrinology, 2013
- Calcium Regulation of Vascular Smooth Muscle Cell–Derived Matrix VesiclesTrends in Cardiovascular Medicine, 2012
- Mechanisms and Clinical Consequences of Vascular CalcificationFrontiers in Endocrinology, 2012
- Role of the Rho pathway in regulating valvular interstitial cell phenotype and nodule formationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Annexin-Mediated Matrix Vesicle Calcification in Vascular Smooth Muscle CellsJournal of Bone and Mineral Research, 2008
- The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve PathobiologyThe American Journal of Pathology, 2007
- Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both?Heart, 2006
- DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate FormationPLOS Biology, 2004
- Annexin-mediated Ca2+ Influx Regulates Growth Plate Chondrocyte Maturation and ApoptosisJournal of Biological Chemistry, 2003